AzTrials
AzTrials

Metabolic FlexibilityNCT04773132

Human Metabolic Flexibility: Its Role in Energy Regulation and Obesity

A study testing Low Protein in people with Metabolic Flexibility, run by Singapore Institute of Food and Biotechnology Innovation at 1 site in Singapore.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Obesity is commonly described as a consequence of excess calorie intake. Conventionally, the physiological variables that have been of extensive interest are food intake and energy expenditure. Read more about this study

Who is it for?
Ages 21 to 35 yearsHealthy volunteers can take part
Conditions the study is for
Metabolic Flexibility
What is being tested?
Low Protein
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
1 siteSingapore
Study dates
19 May 2015to 11 Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 35 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Chinese Male or Female
  • Age between 21-35 years
  • Body mass index 17.5-32.0 kg/m2

Who cannot join

  • People with major chronic disease such as heart disease, cancer or diabetes mellitus
  • People with family history of diabetes
  • People who have intolerances or allergies to study foods
  • Individuals who are taking drugs known to affect glucose metabolism, body fat distribution, appetite, food intake or energy metabolism
  • Individuals who are on a special diet or recently on a weight-lost diet
  • Pregnant women

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • Clinical Nutrition Research Centre

    Singapore, 117599

Other trials in Singapore

About this study

Obesity is commonly described as a consequence of excess calorie intake. Conventionally, the physiological variables that have been of extensive interest are food intake and energy expenditure. Despite decades of research on factors influencing intake and expenditure, to date, no compelling theory has been promulgated to explain why certain humans are more susceptible to weight gain than others. The investigators hypothesize that the measure of an individual's fraction of energy mobilized or deposited as protein (P-ratio), contributes towards an obese morphology and may essentially form a novel approach in understanding the etiology, management and treatment of obesity. In addition, there is a general perception that the consumption of sugar sweetened foods and beverages are one of the major causes of obesity. This study aims to understand metabolic flexibility and the glycemic index of diets in the etiology of obesity. Individual metabolic flexibility may be the key factor that predisposes an individual to obesity. This study is carried out to determine the P-ratio in human subjects.

Read the detailed description

Obesity is commonly described as a consequence of excess calorie intake. Conventionally, the physiological variables that have been of extensive interest are food intake and energy expenditure. Despite decades of research on factors influencing intake and expenditure, to date, no compelling theory has been promulgated to explain why certain humans are more susceptible to weight gain than others. The investigators believe that a measure of an individual's metabolic flexibility towards an obese morphology is essential and forms a novel approach in understanding the etiology, management and treatment of obesity. Payne and Dugdale developed a simple model of energy balance, based on dividing the human body into four compartments, namely "fast" lean tissue (protein), "slow" lean tissue (protein), structural fat, and tissue fat. Notionally, these are considered to act as four separate compartments which interconnect with each other. Body weight is thus simply the sum of the four weights, and metabolic rate is the sum of the separate compartment rates. Any energy deficit in the "balancing compartment" is met by withdrawing tissues from the neighboring fat and lean (muscle) compartments in a proportion which is fixed for any individual. The observed human variability in both the susceptibility to gain weight or to lose weight efficiently on a calorie surplus or restricted diet is thus afforded by using the model developed by Payne and Dugdale for energy balance. P-ratio is calculated on the assumption that body protein is 16% nitrogen and has a metabolizable energy value of 16.7 kJ/g. Thus P-ratio can be calculated as: P- ratio= urinary nitrogen excretion x 6.25 x 16.7 / total energy expenditure. The regulatory control of energy-partitioning between protein and fat is highly variable between individuals, but constant within the same subject. It is this variability in tissue partitioning between lean (protein) and fat that is central to the regulation of body weight. This implies that for a given individual, there is a fixed partitioning of energy between lean (protein) and fat tissue when excess calories are consumed. Using the results of the classical study of human semi-starvation by Keys et al, Dugdale and Payne calculated the individual pattern of tissue mobilization (P-ratio) in these subjects. The P-ratio ranged from 0.03 to 0.60. On the basis of these data, they classified individuals into "metabolically lean" and "metabolically fat". A P-ratio of 0.03 means approximately 3% of the energy loss from this subject's body tissues was derived from protein catabolism and 97% from fat. Thus during excess calorie consumption, 3% of the calories will be deposited as protein and 97% as fat ("metabolically fat"). Similarly a subject with a P-ratio of 0.60 will deposit 60% calories as protein and only 40% as fat ("metabolically lean"). This stratification of "metabolic type" is a novel approach in obesity research, treatment and its management. The current method for the determination of P-ratio is based on subjects undergoing total starvation/fasting, e.g. complete food restriction, ad libitum water intake. This is a highly impractical approach. The investigator's proposal is to develop a more convenient and practical methodology to determine the P-ratio. An individual's Basal Metabolic Rate after a 10 hour overnight fast will approximate the denominator of the P-ratio. Henry et al reported a quantitative relationship between a fasting urine nitrogen loss (FUNL) and obligatory urinary nitrogen loss (OUNL), the ratio FUNL: OUNL remained close to 1.5. OUNL can be measured in urine when a subject is fed a protein free diet. With these two measures, the P-ratio of an individual can be estimated. OUNL is the protein lost in the urine when fed a zero or non-protein diet and fasting urinary loss is the nitrogen lost during starvation/ fasting (FUNL). The investigator's proposed study will be the first real-time study that will utilize the obligatory urine nitrogen loss and BMR to quantitate human P-ratio.

Being tested
Low Protein
Keywords
BMR, P-ratio, Tissue partitioning

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low ProteinOther

    Low protein/protein-free diet for 3 days (Day 1, 2 and Day 3) in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.

Study groups in NCT04773132
Study groupRoleWhat they receive
Low Protein DietExperimentalAll subjects will be given a low protein/protein-free diet in order to deplete the label protein pool. The diet provided will meet the daily energy requirements of all the subjects.
Receives: Other: Low Protein

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weight

    Kg

    Measured: Day 1

  2. Waist Circumference

    cm

    Measured: Day 1

  3. Hip Circumference

    cm

    Measured: Day 1

  4. Body fat

    Percentage

    Measured: Day 1

  5. Estimated visceral adipose tissue area

    cm2

    Measured: Day 1

Secondary outcomes (1)
  1. Height

    cm

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Feb 2021
  2. Study start19 May 2015
  3. Primary completion1 Apr 2016
  4. Study completion11 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
68 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04773132
Sponsor's protocol ID
2014/01182
Other IDs
2014
Status last verified
Feb 2021
First submitted
18 Feb 2021
Last updated
26 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Low Protein in people with Metabolic Flexibility, run by Singapore Institute of Food and Biotechnology Innovation at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weight (time frame: Day 1). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in